Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic, version 2.2021
Mary B. Daly,Tuya Pal,Michael Berry,Saundra S. Buys,Patricia I. Dickson,Susan M. Domchek,Ahmed Elkhanany,Susan Hatters Friedman,Michael Goggins,Mollie L. Hutton,Beth Y. Karlan,Seema A. Khan,Catherine Klein,Wendy Kohlmann,Allison W. Kurian,Christine Laronga,Jennifer K. Litton,Julie S. Mak,Carolyn S. Menendez,Sofia D. Merajver,Barbara S. Norquist,Kenneth Offit,Holly J. Pederson,Gwen Reiser,Leigha Senter-Jamieson,Kristen M. Shannon,Rebecca Shatsky,Kala Visvanathan,Jeffrey N. Weitzel,Myra J. Wick,Kari B. Wisinski,Matthew B. Yurgelun,Susan Darlow,Mary A. Dwyer +33 more
TLDR
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants associated with increased risk of breast, ovarian, and pancreatic cancer and recommended approaches to genetic testing/counseling and management strategies as mentioned in this paper.Abstract:
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants associated with increased risk of breast, ovarian, and pancreatic cancer and recommended approaches to genetic testing/counseling and management strategies in individuals with these pathogenic or likely pathogenic variants. This manuscript focuses on cancer risk and risk management for BRCA-related breast/ovarian cancer syndrome and Li-Fraumeni syndrome. Carriers of a BRCA1/2 pathogenic or likely pathogenic variant have an excessive risk for both breast and ovarian cancer that warrants consideration of more intensive screening and preventive strategies. There is also evidence that risks of prostate cancer and pancreatic cancer are elevated in these carriers. Li-Fraumeni syndrome is a highly penetrant cancer syndrome associated with a high lifetime risk for cancer, including soft tissue sarcomas, osteosarcomas, premenopausal breast cancer, colon cancer, gastric cancer, adrenocortical carcinoma, and brain tumors.read more
Citations
More filters
Journal ArticleDOI
Hereditary Diffuse Gastric Cancer: Updated Clinical Practice Guidelines
Vanessa Blair,Maybelle McLeod,Fátima Carneiro,Daniel G. Coit,Johanna L. D'Addario,Jolanda M. van Dieren,Kirsty L. Harris,Nicoline Hoogerbrugge,Carla Oliveira,Rachel S. van der Post,Julie Arnold,Patrick R. Benusiglio,Tanya M. Bisseling,Alex Boussioutas,Annemieke Cats,Amanda Charlton,Karen E Chelcun Schreiber,Jeremy L. Davis,Massimiliano di Pietro,Rebecca C. Fitzgerald,James M. Ford,Kimberley Gamet,Irene Gullo,Richard H. Hardwick,David G. Huntsman,Pardeep Kaurah,Sonia S. Kupfer,Andrew Latchford,Paul F. Mansfield,Takeshi Nakajima,Susan Parry,Jeremy Rossaak,Haruhiko Sugimura,Magali Svrcek,Marc Tischkowitz,Toshikazu Ushijima,Hidetaka Yamada,Han Kwang Yang,Adrian Claydon,Joana Figueiredo,Karyn Paringatai,Raquel Seruca,Nicola Bougen-Zhukov,Tom Brew,Simone Busija,Patrícia Carneiro,Lynn DeGregorio,Helen L. Fisher,Erin Gardner,Tanis D Godwin,Katharine Nichole Holm,Bostjan Humar,C. J. Lintott,Elizabeth C. Monroe,Mark D. Muller,Enrique Norero,Yasmin Nouri,Joana Paredes,Joao Sanches,Emily Schulpen,Ana Sofia Ribeiro,Andrew A. Sporle,James Whitworth,Liying Zhang,Anthony E. Reeve,Parry Guilford +65 more
TL;DR: In this article, the authors present updated clinical practice guidelines for hereditary diffuse gastric cancer (HDGC) from the International Gastric Cancer Linkage Consortium (IGCLC), which recognise the emerging evidence of variability in Gastric cancer risk between families with HDGC, and increased experience of managing long-term sequelae of total gastrectomy in young patients.
Journal ArticleDOI
Cancer Risks Associated With <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants
TL;DR: In this paper , age-specific risk estimates of cancers other than female breast and ovarian cancers associated with pathogenic variants (PVs) in BRCA1 and BRCa2 for effective cancer risk management were provided.
Journal ArticleDOI
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the Clinical Practice of Hereditary Colorectal Cancer
Naohiro Tomita,Hideyuki Ishida,Kohji Tanakaya,Tatsuro Yamaguchi,Kensuke Kumamoto,Toshiaki Tanaka,Takao Hinoi,Yasuyuki Miyakura,Hirotoshi Hasegawa,Tetsuji Takayama,Hideki Ishikawa,Takeshi Nakajima,Akiko Chino,Hideki Shimodaira,Akira Hirasawa,Yoshiko Nakayama,Shigeki Sekine,Kazuo Tamura,Kiwamu Akagi,Yuko Kawasaki,Hirotoshi Kobayashi,Masami Arai,Michio Itabashi,Yojiro Hashiguchi,Kenichi Sugihara +24 more
TL;DR: The first guideline for hereditary colorectal cancer (HCRC) was prepared by the Japanese Society for Cancer of the Colon and Rectum (JSCCR), published in 2012 and revised in 2016 as discussed by the authors.
Journal ArticleDOI
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.
Silke Gillessen,Andrew J. Armstrong,Gerhardt Attard,Tomasz M. Beer,Himisha Beltran,Anders Bjartell,Alberto Bossi,Alberto Briganti,Robert G. Bristow,Muhammad Bulbul,Orazio Caffo,Kim N. Chi,Caroline S. Clarke,Noel W. Clarke,Ian D. Davis,Johann S. de Bono,Ignacio Duran,Rosalind A. Eeles,Eleni Efstathiou,Jason A. Efstathiou,O. Ekeke,Christopher H. Evans,Stefano Fanti,Felix Y. Feng,Karim Fizazi,Mark Frydenberg,Daniel J. George,Martin E. Gleave,Susan Halabi,D. Heinrich,C. Higano,Michael S Hofman,Maha Hussain,Nicholas D. James,Robert Jones,Ravindran Kanesvaran,Raja B. Khauli,Laurence Klotz,Raya Leibowitz,Christopher J. Logothetis,Fernando C. Maluf,Robin Millman,Alicia K. Morgans,Michael J. Morris,Nicolas Mottet,Hind Mrabti,Declan G. Murphy,Vedang Murthy,William Oh,Piet Ost,Joe M. O'Sullivan,Anwar R. Padhani,Chris Parker,Darren M.C. Poon,Colin C. Pritchard,Danny M. Rabah,Dana E. Rathkopf,Robert E. Reiter,M.L. Rubin,Charles J. Ryan,Fred Saad,Juan Pablo Sade,Oliver Sartor,Howard I. Scher,Neal D. Shore,Iwona Skoneczna,Eric J. Small,Matthew R. Smith,Howard R. Soule,Daniel E. Spratt,Cora N. Sternberg,H. Suzuki,Christopher Sweeney,Matthew R. Sydes,Mary-Ellen Taplin,Derya Tilki,Bertrand Tombal,Levent Türkeri,Hiroji Uemura,Hirotsugu Uemura,Inge M. van Oort,Kosj Yamoah,Dingwei Ye,Almudena Zapatero,Aurelius Omlin +84 more
TL;DR: The 2019 Advanced Prostate Cancer Consensus Conference (APCCC) as mentioned in this paper addressed three major areas of controversy related to management of advanced prostate cancer: newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), the use of prostate-specific membrane antigen ligands in diagnostics and therapy, and molecular characterisation of tissue and blood.
Journal ArticleDOI
BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside
Stergios Boussios,Elie El Rassy,Michele Moschetta,Aruni Ghose,Sola Adeleke,Elisabet Sánchez,Matin Sheriff,Cyrus Chargari,Nicholas Pavlidis +8 more
TL;DR: The mechanisms of DDR, the potential for genomic analysis of ovarian and prostate cancer, and therapeutics of PARP inhibitors, along with predictive biomarkers are explored, with a major concern regarding the need to identify reliable biomarkers predictive of treatment response.
References
More filters
Journal ArticleDOI
p53, the Cellular Gatekeeper for Growth and Division
TL;DR: The author regrets the lack of citations for many important observations mentioned in the text, but their omission is made necessary by restrictions in the preparation of review manuscripts.
Journal ArticleDOI
Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms
David Malkin,Frederick P. Li,Frederick P. Li,Louise C. Strong,Joseph F. Fraumeni,Camille E. Nelson,Camille E. Nelson,David H. Kim,Jayne Kassel,Magdalena A. Gryka,Farideh Z. Bischoff,Michael A. Tainsky,Stephen H. Friend +12 more
TL;DR: Germ line p53 mutations have been detected in all five LFS families analyzed and can now be examined in additional families with LFS, and in other cancer patients and families with clinical features that might be attributed to the mutation.
Journal ArticleDOI
Mutational landscape and significance across 12 major cancer types
Cyriac Kandoth,Michael D. McLellan,Fabio Vandin,Kai Ye,Beifang Niu,Charles Lu,Mingchao Xie,Qunyuan Zhang,Joshua F. McMichael,Matthew A. Wyczalkowski,Mark D.M. Leiserson,Christopher A. Miller,John S. Welch,Matthew J. Walter,Michael C. Wendl,Timothy J. Ley,Richard K. Wilson,Benjamin J. Raphael,Li Ding +18 more
TL;DR: Data and analytical results for point mutations and small insertions/deletions from 3,281 tumours across 12 tumour types are presented as part of the TCGA Pan-Cancer effort, and clinical association analysis identifies genes having a significant effect on survival.
Journal ArticleDOI
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies
Antonis C. Antoniou,Paul D.P. Pharoah,Steven A. Narod,Harvey A. Risch,Jorunn E. Eyfjord,John L. Hopper,Niklas Loman,Håkan Olsson,Oskar T. Johannsson,Åke Borg,Barbara Pasini,Paolo Radice,Siranoush Manoukian,Diana Eccles,Nelson L.S. Tang,E. Olah,Hoda Anton-Culver,Ellen Warner,Jan Lubinski,Jacek Gronwald,Bohdan Górski,Hrafn Tulinius,Steinunn Thorlacius,Hannaleena Eerola,Heli Nevanlinna,Kirsi Syrjäkoski,Olli Kallioniemi,Deborah J. Thompson,Christopher H. Evans,Julian Peto,Julian Peto,Fiona Lalloo,D G R Evans,Douglas F. Easton +33 more
TL;DR: Risks in carriers were higher when based on index breast cancer cases diagnosed at <35 years of age and for variation in risk by mutation position for both genes, and some evidence for a reduction in risk in women from earlier birth cohorts is found.
Related Papers (5)
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Karoline Kuchenbaecker,Karoline Kuchenbaecker,John L. Hopper,Daniel R. Barnes,Kelly-Anne Phillips,T.M. Mooij,Marie-José Roos-Blom,Marie-José Roos-Blom,Sarah Jervis,Sarah Jervis,Flora E. van Leeuwen,Roger L. Milne,Roger L. Milne,Nadine Andrieu,David E. Goldgar,Mary Beth Terry,Matti A. Rookus,Douglas F. Easton,Antonis C. Antoniou,Lesley McGuffog,D. Gareth Evans,Daniel Barrowdale,Debra Frost,Julian Adlard,Kai-ren Ong,Louise Izatt,Marc Tischkowitz,Ros Eeles,Rosemarie Davidson,Shirley Hodgson,Steve Ellis,Catherine Noguès,Christine Lasset,Dominique Stoppa-Lyonnet,Dominique Stoppa-Lyonnet,Jean-Pierre Fricker,Laurence Faivre,Pascaline Berthet,Maartje J. Hooning,Lizet E. van der Kolk,Carolien M. Kets,Muriel A. Adank,Esther M. John,Wendy K. Chung,Irene L. Andrulis,Irene L. Andrulis,Melissa C. Southey,Mary B. Daly,Saundra S. Buys,Ana Osorio,Christoph Engel,Karin Kast,Rita K. Schmutzler,Trinidad Caldés,Anna Jakubowska,Jacques Simard,Michael Friedlander,Sue-Anne McLachlan,Sue-Anne McLachlan,Eva Machackova,Lenka Foretova,Yen Y. Tan,Yen Y. Tan,Christian F. Singer,Edith Olah,Anne-Marie Gerdes,Brita Arver,Håkan Olsson +67 more
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies
Antonis C. Antoniou,Paul D.P. Pharoah,Steven A. Narod,Harvey A. Risch,Jorunn E. Eyfjord,John L. Hopper,Niklas Loman,Håkan Olsson,Oskar T. Johannsson,Åke Borg,Barbara Pasini,Paolo Radice,Siranoush Manoukian,Diana Eccles,Nelson L.S. Tang,E. Olah,Hoda Anton-Culver,Ellen Warner,Jan Lubinski,Jacek Gronwald,Bohdan Górski,Hrafn Tulinius,Steinunn Thorlacius,Hannaleena Eerola,Heli Nevanlinna,Kirsi Syrjäkoski,Olli Kallioniemi,Deborah J. Thompson,Christopher H. Evans,Julian Peto,Julian Peto,Fiona Lalloo,D G R Evans,Douglas F. Easton +33 more
Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality
Susan M. Domchek,Tara M. Friebel,Christian F. Singer,D. Gareth Evans,Henry T. Lynch,Claudine Isaacs,Judy Garber,Susan L. Neuhausen,Ellen T. Matloff,Rosalind A. Eeles,Gabriella Pichert,Laura Van T'veer,Nadine Tung,Jeffrey N. Weitzel,Fergus J. Couch,Wendy S. Rubinstein,Wendy S. Rubinstein,Patricia A. Ganz,Mary B. Daly,Olufunmilayo I. Olopade,Gail E. Tomlinson,Joellen M. Schildkraut,Joanne L. Blum,Timothy R. Rebbeck +23 more